1
|
Pachón-Angona I, Refouvelet B, Andrýs R, Martin H, Luzet V, Iriepa I, Moraleda I, Diez-Iriepa D, Oset-Gasque MJ, Marco-Contelles J, Musilek K, Ismaili L. Donepezil + chromone + melatonin hybrids as promising agents for Alzheimer's disease therapy. J Enzyme Inhib Med Chem 2019; 34:479-489. [PMID: 30712420 PMCID: PMC6366423 DOI: 10.1080/14756366.2018.1545766] [Citation(s) in RCA: 34] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/25/2018] [Revised: 10/21/2018] [Accepted: 11/04/2018] [Indexed: 12/13/2022] Open
Abstract
We describe herein the design, multicomponent synthesis and biological studies of new donepezil + chromone + melatonin hybrids as potential agents for Alzheimer's disease (AD) therapy. We have identified compound 14n as promising multitarget small molecule showing strong BuChE inhibition (IC50 = 11.90 ± 0.05 nM), moderate hAChE (IC50 = 1.73 ± 0.34 μM), hMAO A (IC50 = 2.78 ± 0.12 μM), and MAO B (IC50 = 21.29 ± 3.85 μM) inhibition, while keeping a strong antioxidant power (3.04 TE, ORAC test). Consequently, the results reported here support the development of new multitarget Donepezil + Chromone + Melatonin hybrids, such as compound 14n, as a potential drug for AD patients cure.
Collapse
Affiliation(s)
- Irene Pachón-Angona
- Neurosciences intégratives et cliniques, Pôle Chimie Organique et Thérapeutique, University Bourgogne Franche-Comté, Besançon, France
| | - Bernard Refouvelet
- Neurosciences intégratives et cliniques, Pôle Chimie Organique et Thérapeutique, University Bourgogne Franche-Comté, Besançon, France
| | - Rudolf Andrýs
- Faculty of Science, Department of Chemistry, University of Hradec Kralove, Hradec Kralove, Czech Republic
| | - Helène Martin
- PEPITE EA4267, Laboratoire de Toxicologie Cellulaire, University Bourgogne Franche-Comté, Besançon, France
| | - Vincent Luzet
- Neurosciences intégratives et cliniques, Pôle Chimie Organique et Thérapeutique, University Bourgogne Franche-Comté, Besançon, France
| | - Isabel Iriepa
- Department of Organic Chemistry and Inorganic Chemistry, Alcalà University, Madrid, Spain
- Institute of Chemical Research Andrés M. del Río, Alcalà University, Madrid, Spain
| | - Ignacio Moraleda
- Department of Organic Chemistry and Inorganic Chemistry, Alcalà University, Madrid, Spain
| | - Daniel Diez-Iriepa
- Department of Organic Chemistry and Inorganic Chemistry, Alcalà University, Madrid, Spain
- Institute of Chemical Research Andrés M. del Río, Alcalà University, Madrid, Spain
| | - María-Jesús Oset-Gasque
- Instituto de Investigación en Neuroquímica, Universidad Complutense de Madrid, Madrid, Spain
- Department of Biochemistry and Molecular Biology, School of Pharmacy, Plaza de Ramòn y Cajal, Madrid, Spain
| | | | - Kamil Musilek
- Faculty of Science, Department of Chemistry, University of Hradec Kralove, Hradec Kralove, Czech Republic
| | - Lhassane Ismaili
- Neurosciences intégratives et cliniques, Pôle Chimie Organique et Thérapeutique, University Bourgogne Franche-Comté, Besançon, France
| |
Collapse
|